skip to primary navigationskip to content

David Rubinsztein

Autophagy and neurodegeneration

The biology of diseases associated with protein misfolding and intracellular aggregation, using Huntington’s disease (HD) as a paradigm

Intracellular protein misfolding/aggregation are features of many late-onset neurodegenerative diseases, called proteinopathies. These include Alzheimer’s disease, Parkinson’s disease, tauopathies, and polyglutamine expansion diseases (like Huntington’s disease (HD) and various spinocerebellar ataxias (SCAs)).  Currently, there are no effective strategies that slow/prevent the neurodegeneration resulting from these diseases in humans.

We are currently employing a range of approaches to address this issue, including conventional biochemistry and cell biology, zebrafish genetic knockdowns and genome-wide Drosophila modifier screens. We are trying to identify pathways that may have broad relevance to a range of neurodegenerative diseases (e.g. Sarkar et al. (2011) Mol Cell 43, 19-32). 

Therapeutic strategies for these diseases

The mutations causing HD and many proteinopathies confer novel toxic functions on the specific protein, and disease severity frequently correlates with expression levels. Thus, it is important to understand the factors regulating the levels of these aggregate-prone proteins.

(Macro) autophagy is a bulk degradation process that mediates the clearance of long-lived proteins and organelles (reviewed in Rubinsztein et al. (2011) Cell 146, 682-695). Autophagosomes are formed by double-membraned structures, which engulf portions of cytoplasm. Autophagosomes ultimately fuse with lysosomes, where their contents are degraded.

autophagy model
Schematic overview of autophagy


We have become increasingly involved in studying autophagy, since the time of our discovery that it regulates the levels of intracytoplasmic aggregate-prone proteins that cause many neurodegenerative diseases, including Huntington’s disease, point mutations in alpha-synuclein (causing forms of Parkinson’s disease), and wild-type and mutant forms of tau (causing various dementias) (reviewed in Rubinsztein et al. (2012) Nature Reviews Drug Discovery 11:709-730). The clearance of such substrates is retarded in cell models when autophagy is compromised. For Huntington’s disease and a range of related neurodegenerative diseases, we are pursuing our findings that the toxicity of these proteins in cells, Drosophila, zebrafish and mice can be alleviated by enhancing their removal by autophagy (Ravikumar et al. (2004) Nature Genetics  36: 585-595). We are trying to identify safe and effective strategies for exploiting autophagy upregulation in order to enhance the removal of the toxic intracytoplasmic proteins that cause many of these diseases (e.g. Sarkar et al. (2007) Nature Chemical Biology 3: 331-338; Williams et al. (2008) Nature Chemical Biology 4: 295-305).

The cell biology of autophagy and its relevance to human physiology and disease, with a focus on the nervous system  

We have identified the plasma membrane as a source of autophagosome membrane (Ravikumar et al. (2010) Nature Cell Biology 12:747-757) and have characterised early events in autophagosome biogenesis (e.g. Moreau et al. (2011) Cell 146:303-317; Puri et al. (2013) Cell 154: 1285-1299). We have studied how lysosomal positioning regulates autophagy (Korolchuk et al. (2011) Nature Cell Biology 13:453-460).

We have found that autophagy may be inhibited in various neurodegenerative diseases (e.g. Winslow et al. (2010) J Cell Biol 190:1023-1037) and have been trying to elucidate the pathological consequences of autophagy compromise — our data suggest that autophagy inhibition impairs flux through the ubiquitin-proteasome degradation pathway (Korolchuk et al. (2009) Molecular Cell 33:517-527).

Rubinsztein lab


Key papers:

C Puri,M Vicinanza, A Ashkenazi, MJ Gratian, Q Zhang, CF Bento, M Renna, FM Menzies and DC Rubinsztein (2018) The RAB11A-positive compartment is a primary platform for autophagosome assembly mediated by WIPI2 recognition of PI3P-RAB11A. Developmental Cell 45:114-131

A Ashkenazi, CF Bento, T Ricketts, M Vicinanza, F Siddiqi, M Pavel, F Squitieri, MC Hardenberg, S Imarisio, FM Menzies & DC Rubinsztein (2017) Polyglutamine tracts regulate beclin 1-dependent autophagy. Nature 545:108-111.

M Jimenez-Sanchez, W Lam, M Hannus, B Sönnichsen, S Imarisio, A Fleming, A Tarditi, F Menzies, T Ed Dami, C Xu, E Gonzalez-Couto, G Lazzeroni, F Heitz,  D Diamanti, L Massai, VP Satagopam, G Marconi, C Caramelli, A Nencini, M Andreini, GL Sardone6, NP Caradonna, V Porcari, C Scali, R Schneider, G Pollio, CJ O’Kane, A Caricasole and DC Rubinsztein. siRNA screen identifies QPCT as a druggable target for Huntington’s disease. Nature Chem. Biol. 11, 347-354 (2015).

M Vicinanza, VI Korolchuk, A Ashkenazi, C Puri, FM Menzies, JH Clarke and DC Rubinsztein. PI(5)P regulates autophagosome biogenesis. Mol. Cell 57, 219-234 (2015).

C Puri, M Renna, C Figueira Bento, K Moreau and DC Rubinsztein Diverse autophagosome membrane sources coalesce in recycling endosomes. Cell 154, 1285-1299 (2013).

S Luo, M Garcia-Arencibia, R Zhao, C Puri, PPC Toh, O Sadiq and DC Rubinsztein. Bim inhibits autophagy by recruiting Beclin 1 to microtubules. Mol. Cell 47, 359-370 (2012).

K Moreau, B Ravikumar, M Renna, C Puri, and DC Rubinsztein. Autophagosome precursor maturation requires homotypic fusion. Cell 146, 303-317 (2011).

S Sarkar, VI Korolchuk, M Renna, S Imarisio, A Fleming, A Williams, M Garcia-Arencibia, C Rose, S Luo, BR Underwood, G Kroemer, CJ O’Kane, and DC Rubinsztein Complex inhibitory effects of nitric oxide on autophagy. Mol. Cell 43, 19-32 (2011).

VI Korolchuk, S Saiki, M Lichtenberg, FH Siddiqi, EA Roberts, S Imarisio, L Jahreiss, S Sarkar, M Futter, FM Menzies, CJ O’Kane, V Deretic and DC Rubinsztein Lysosomal positioning coordinates cellular nutrient responses. Nature Cell Biol. 13, 453-460 (2011).

B Ravikumar, K Moreau, L Jahreiss, C Puri and DC Rubinsztein. Plasma membrane contributes to the formation of pre-autophagosomal structures. Nature Cell Biol. 12:747-757 (2010).

AR Winslow, C-W Chen, S Corrochano, A Acevedo-Arozena, DE Gordon, A A Peden, M Lichtenberg, FM Menzies, B Ravikumar, S Imarisio, S Brown, CJ O’Kane, and DC Rubinsztein Alpha-synuclein impairs macroautophagy: implications for Parkinson’s disease. J. Cell Biol. 190, 1023-1037 (2010).

TJ van Ham, M Holmberg, A van der Goot, E Teuling, M Garcia-Arencibia, H Kim, D Du, KL Thijssen, M Wiersma, R Burggraaff, P van Bergeijk, J van Rheenen, G Jerre van Veluw, RMW Hofstra, DC Rubinsztein and EAA Nollen. Identification of MOAG-4/SERF as a  regulator of age-related proteotoxicity. Cell 142, 601-612 (2010).

VI Korolchuk, A Mansilla, FM Menzies and DC Rubinsztein Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol. Cell 33, 517-527 (2009).

A Williams, S Sarkar, P Cuddon, EK Ttofi, S Saiki, FH. Siddiqi, L Jahreiss, A Fleming, D Pask, P Goldsmith, CJ O’Kane, RA Floto and DC Rubinsztein Novel targets for Huntington’s disease in an mTOR-independent autophagy pathway.  Nature Chem. Biol. 4, 295-305 (2008).

S Sarkar, EO Perlstein, S Imarisio, S Pineau, A Cordenier, RL Maglathlin, JA Webster, TA Lewis, CJ O’Kane, SL Schreiber, and DC Rubinsztein Small molecules enhance autophagy and reduce toxicity in Huntington’s disease models. Nature Chem. Biol. 3, 331-338 (2007).

S Sarkar, RA Floto, Z Berger, S Imarisio, A Cordenier, M Pasco, LJ Cook and DC Rubinsztein. Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 170, 1101-1111 (2005).

B Ravikumar, A Acevedo-Arozena, S Imarisio, Z Berger, C Vacher, CJ O’Kane, SDM Brown and DC Rubinsztein Dynein mutations impair autophagic clearance of aggregate-prone proteins. Nature Genetics 37, 771-776 (2005).

S Luo, C Vacher, JE Davies and DC Rubinsztein Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. J Cell Biol. 169, 647-656 (2005).

JE Davies, L Wang, L Garcia-Oroz, LJ Cook, C Vacher, DG O’Donovan and DC Rubinsztein. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nature Med. 6, 672-677 (2005).

B Ravikumar, C Vacher, Z Berger, JE Davies, S Luo, LG Oroz, F Scaravilli, DF Easton, R Duden, CJ O’Kane, and DC Rubinsztein. mTOR inhibition induces autophagy and reduces toxicity of the Huntington’s disease mutation in Drosophila and mouse models. Nature Genetics  36, 585-595 (2004).





David Rubinsztein

David Rubinsztein FMedSci FRS

CIMR Deputy Director

Professor of Molecular Neurogenetics

UK Dementia Research Institute Professor

Honorary Consultant in Medical Genetics

Department: Medical Genetics



Plain English

Neurodegenerative diseases such as Alzheimer’s and Huntington’s Disease arise when particular proteins accumulate that are not folded properly. Our research goal is to understand the links between these diseases and autophagy — the bulk recycling process that degrades proteins and particular parts of the cell. We currently focus on: understanding how autophagy is induced using several animal models; and possible ways to ramp up this process in order to remove toxic proteins and avoid the development of neurodegenerative disease.

Group members

Vicky Barratt · Sarah de Jager · Alvin Djajadikerta · Patrick Ejlerskov · Angeleen Fleming · Hee-Yeon Jeon · So Jung Park · Cansu Karabiyik · Ingrid Lager Gotaas · Ana Lopez Ramirez · Sandra Malmgren Hill · Claudia Puri · Gautam Runwal · Gentzane Sanchez Elexpuru · Ji Hyun Shin · Farah Siddiqi · Sungmin Son · Eleanna Stamatakou · Yoshinori Tanaka · Sylwia Tyrkalska · Mariella Vicinanza · Sarah Williams · Lidia Wrobel · Ye Zhu


UK Dementia Research Institute

(funded by Medical Research Council, Alzheimer's Research UK, Alzheimer's Society)

Alzheimer's Research UK

European Union FP7

Tau Consortium

National Institutes for Health Research - Cambridge Biomedical Research Centre

Rosetrees Trust

Addenbrooke's Charitable Trust